Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials

Magnus O. Wijkman1,2, Brian Claggett1, Muthiah Vaduganathan1, Jonathan W. Cunningham1, Rasmus Rørth3, Alice Jackson4, Milton Packer5,6, Michael Zile7, Jean Rouleau8, Karl Swedberg9, Martin Lefkowitz10, Sanjiv J. Shah11, Marc A. Pfeffer1, John J. V. McMurray4 and Scott D. Solomon1*

Abstract
Background: Compared with enalapril, sacubitril/valsartan lowered HbA1c and reduced new insulin therapy in patients with heart failure with reduced ejection fraction (HFrEF) and diabetes in the PARADIGM-HF trial. We sought to assess the glycemic effects of sacubitril/valsartan in heart failure with preserved ejection fraction (HFpEF) and diabetes, and across the spectrum of left ventricular ejection fraction (LVEF) in heart failure and diabetes.

Methods: We compared the effect of sacubitril/valsartan, relative to valsartan, on HbA1c, new insulin therapy and hypoglycemia in the randomized controlled trial PARAGON-HF, and performed pooled analyses of PARAGON-HF and PARADIGM-HF.

Results: Among 2395 patients with HFpEF and diabetes in PARAGON-HF, sacubitril/valsartan compared with valsartan reduced HbA1c (baseline-adjusted between-group difference in HbA1c change at 48 weeks: −0.24%, 95% CI −0.33 to −0.16%, P < 0.001). Numerically, new insulin treatment was initiated less often in the sacubitril/valsartan group than in the valsartan group, but the difference was not statistically significant (12.8% vs. 16.1%; HR: 0.80, 95% CI 0.62–1.02, P = 0.07). Hypoglycemia adverse event reports were low, but more frequent in those receiving sacubitril/valsartan than in the valsartan group (4.2% vs. 2.6%; HR: 1.64, 95% CI 1.05–2.56, P = 0.030). In a pooled analysis of PARAGON-HF and PARADIGM-HF, the effect of sacubitril/valsartan on change in HbA1c was not significantly modified by LVEF (Pinteraction = 0.56). Across the spectrum of LVEF, sacubitril/valsartan reduced new insulin therapy (HR: 0.75, 95% CI 0.63–0.89, P < 0.001), compared with enalapril or valsartan.

Conclusions: Sacubitril/valsartan reduced HbA1c and new insulin therapy in patients with heart failure and diabetes across the spectrum of LVEF but may be associated with a slightly higher risk for hypoglycemia.

Trial registration ClinicalTrials.gov NCT01920711

Keywords: Heart failure, Diabetes, Sacubitril/valsartan, Hypoglycemia

*Correspondence: ssolomon@bwh.harvard.edu
1 Cardiovascular Division, Brigham & Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
7], and the requirement for insulin in particular has been associated with an increased risk for adverse cardiovascular outcomes in this population [5, 8, 9].

Treatment with the angiotensin receptor neprilysin inhibitor sacubitril/valsartan decreases morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF) [10], and has also shown benefit in some patients with HfPpEF [11]. Sacubitril/valsartan has recently received an expanded indication by the Food and Drug Administration (FDA) for treatment of chronic heart failure in a broader range of patients, with greatest benefits noted in patients with left ventricular ejection fraction (LVEF) below normal. Sacubitril/valsartan has previously been shown to reduce HbA1c levels and the need for insulin initiation in patients with HFrEF and diabetes [12] in the PARADIGM-HF trial. Furthermore, sacubitril/valsartan has been shown to improve measures of insulin sensitivity in obese patients who did not have diabetes or heart failure [13]. In the present study, we compared the effect of sacubitril/valsartan with that of valsartan on HbA1c, new use of antihyperglycemic drugs, and risk for hypoglycemia in patients with HFpEF and diabetes who participated in the PARAGON-HF trial. To better understand the impact of sacubitril/valsartan on glycemic control across the spectrum of LVEF, and to refine the estimates of the treatment effects in a larger sample, we also assessed these outcomes in a pooled analysis of patients from the PARAGON-HF and PARADIGM-HF trials.

**Methods**

**Patients and study design**

The PARAGON-HF trial (ClinicalTrials.gov NCT01920711) was a randomized, double-blind, active-controlled event-driven clinical trial that compared the efficacy and safety of sacubitril/valsartan with that of valsartan in 4796 patients with symptomatic HFpEF. As described in detail previously [14], patients were required to be at least 50 years old, to have LVEF of at least 45% within 6 months of screening, to have symptoms of heart failure corresponding to NYHA class II to IV, to have required diuretic therapy for at least 30 days before screening, and to have elevated levels of NT-proBNP and echocardiographic evidence of either left ventricular hypertrophy or left atrial enlargement or both. Patients were not eligible for inclusion if they had a prior LVEF of less than 40% or an alternative diagnosis that could explain their symptoms, but there were no inclusion or exclusion criteria related to diabetes, use of glucose-lowering drugs, or glycemic control [14]. Patients who had tolerated two sequential single-blinded run-in periods (valsartan as monotherapy at half the target dose followed by sacubitril/valsartan at half the target dose) were randomized to double-blinded treatment with either sacubitril/valsartan 97/103 mg bid or valsartan 160 mg bid. The primary and secondary outcomes of the PARAGON-HF trial have been published previously [11]. The PARADIGM-HF trial was a randomized clinical trial that compared the efficacy and safety of sacubitril/valsartan with that of enalapril in 8399 patients with HFrEF [10, 15].

**Definitions of diabetes, glucose lowering medications and glycemic control**

For this secondary analysis of the PARAGON-HF trial, patients were classified as having diabetes at baseline if at least one of the following three criteria were met: self-reported history of diabetes at screening, use of antihyperglycemic medications, or HbA1c of 6.5% or higher at randomization. The following medications were defined as antihyperglycemic drugs: insulin, biguanides, sulfonylureas, alpha-glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and glinides. Fixed combinations of oral drugs (used by 92 participants) were categorized into their component classes. Assessments of glycemic control (by HbA1c measurements) and of medication use were performed at the randomization visit and after 48, 96 and 144 weeks. HbA1c was measured by the BioRad D-10 ion-exchange high-performance liquid chromatography method [16]. During follow-up, the start dates for new use of antihyperglycemic drugs were recorded. New-onset diabetes was an adjudicated end-point in PARAGON-HF, which required at least one of the following criteria to be fulfilled: fasting plasma glucose ≥ 126 mg/dl on two occasions; HbA1c ≥ 6.5% on two occasions; fasting plasma glucose ≥ 126 mg/dl followed by HbA1c ≥ 6.5% (or vice versa); random non-fasting glucose ≥ 200 mg/dl and subsequent fasting plasma glucose ≥ 126 mg/dl; two-hour post load glucose ≥ 200 mg/dl after oral glucose tolerance test with an equivalent of 75 g of glucose and either a random (non-fasting) glucose ≥ 200 mg/dl on a different day or a fasting plasma glucose ≥ 126 mg/dl on a different day; confirmed use of diabetes drugs. Thus, the adjudicated new-onset diabetes events represented diabetes diagnosed in clinical practice outside of the study protocol as reported by the investigators and were not based on HbA1c measurements obtained as part of the study protocol. Hypoglycemia was not an adjudicated end-point, but was assessed as investigator-reported adverse events.
Statistics
Continuous variables were summarized as mean ± standard deviation, or as median [IQR], and categorical variables were summarized using counts and percentages. Baseline between-group differences were tested for statistical significance with Student’s t-test, Wilcoxon’s rank-sum test or with the Chi-square test, as appropriate. Between-group differences in change in HbA1c from randomization to each of the follow-up measurements were assessed with linear regression models in which change in HbA1c was the outcome, treatment group was the predictor, and randomization HbA1c value was a covariate. Treatment-induced reductions in levels of circulating natriuretic peptides correlate with therapeutic benefits in terms of reduced risk for heart failure hospitalizations [17], and in both PARAGON-HF [18] and PARADIGM-HF [19], larger reductions of this biomarker were observed with sacubitril/valsartan, and were predictive of reduced morbidity and mortality rates. Therefore, to assess the possible contribution of improvements in heart failure severity to changes in HbA1c, we performed a separate linear regression model which adjusted additionally for simultaneous changes in levels of NT-proBNP. Overall differences between treatment groups regarding change in HbA1c during follow-up were tested for statistical significance with a longitudinal mixed model, with patient-level random intercept terms, fixed effects of treatment and time as a continuous variable, which assumed an unstructured covariance pattern. The impact of treatment on time to new use of antihyperglycemic medications, and on time to first hypoglycemic adverse events, was assessed with Cox proportional hazards models. Kaplan–Meier curves were used to visualize the cumulative incidence of new use of antihyperglycemic medications and of first hypoglycemic adverse events over time. Pooled analyses of the primary outcomes of the PARAGON-HF and PARADIGM-HF trials were pre-specified, and have been published previously [20]. In the present study, we pooled patient-level data of the two trials to assess potential interactions between LVEF and the treatment effects of sacubitril/valsartan on HbA1c change and on new use of antihyperglycemic drugs and on first hypoglycemic adverse events, and to calculate pooled estimates of the effect of treatment on these outcomes. The treatment effects of sacubitril/valsartan vs. control (estimated rate ratios and 95% confidence intervals obtained from negative binomial regression models) were estimated as a function of LVEF using restricted cubic splines with three knots. We considered two-sided P values < 0.05 as evidence for statistical significance. Statistical analyses were performed in STATA, version 14 (College Station, TX).

Results
Baseline characteristics
The baseline characteristics of the PARAGON-HF participants are presented by diabetes status in Additional file 1: Table S1. As shown in Additional file 1: Fig. S1, there were 2395 patients who were identified as having diabetes according to their medical history (n = 2062) and/or use of antihyperglycemic drugs (n = 1761) and/or having HbA1c ≥ 6.5% (n = 1816). Patients with diabetes were, on average, younger, had higher systolic blood pressure, and were more likely to be male, to be obese, to have had a myocardial infarction, and to have been hospitalized for heart failure. In patients with diabetes, baseline characteristics were similar between randomization groups (Table 1). Metformin was the most frequently used glucose-lowering medication (used by 1135 patients or 47.4% of the patients with diabetes) followed by insulin (used by 657 patients or 27.4% of the patients with diabetes) and sulfonylureas (used by 480 patients or 20.0% of the patients with diabetes). There were 634 patients with diabetes (312 in the valsartan group and 322 in the sacubitril/valsartan group, P = 0.90) who did not use any antihyperglycemic medications at the randomization visit.

Changes in HbA1c
At randomization, HbA1c values were available in all but one patient with diabetes, and there was no significant difference in mean HbA1c values between the sacubitril/valsartan and the valsartan groups (7.37 ± 1.48% vs. 7.32 ± 1.43%, P = 0.44). Mean values of HbA1c at randomization and at weeks 48, 96 and 144 are shown in Fig. 1 and in Table 2 by randomization groups. Overall, there was a significantly larger reduction in HbA1c in the sacubitril/valsartan group than in the valsartan group (P from mixed model for equality of HbA1c slopes = 0.036). The baseline-adjusted between-group difference in changes in mean HbA1c values was largest at week 48 (−0.24%, 95% CI −0.33 to −0.16%, P < 0.001). In patients who also had available data for NT-proBNP at randomization and at week 48 (n = 1489), this difference remained significant after additional adjustment for change in NT-proBNP (−0.20, 95% CI −0.31 to −0.10, P < 0.001). Baseline BMI did not significantly modify the treatment effect of sacubitril/valsartan compared with valsartan on HbA1c (Pinteraction = 0.44). There was no significant association between change in HbA1c and change in eGFR (P = 0.64). The difference between treatment-groups was attenuated over time but remained statistically significant also at week 96 and 144 (Table 2). In
Table 1  Baseline characteristics of PARAGON-HF participants with diabetes by randomization

| Demographics       | Valsartan, n = 1184 | Sacubitril/valsartan, n = 1211 | P     |
|--------------------|---------------------|--------------------------------|-------|
| Age, years         | 72.0 ± 8.3          | 72.1 ± 8.3                     | 0.61  |
| Female, n (%)      | 588 (49.7%)         | 593 (49.0%)                    | 0.73  |
| Race/ethnicity, n (%) |                    |                                | 0.63  |
| Asian              | 153 (12.9%)         | 165 (13.6%)                    |       |
| Black or African American | 34 (2.9%)    | 27 (2.2%)                      |       |
| Other              | 42 (3.5%)           | 50 (4.1%)                      |       |
| White              | 955 (80.7%)         | 969 (80.0%)                    |       |
| Enrollment region, n (%) |                |                                | 0.84  |
| Asia/Pacific       | 192 (16.2%)         | 209 (17.3%)                    |       |
| Central Europe     | 444 (37.5%)         | 444 (36.7%)                    |       |
| Latin America      | 75 (6.3%)           | 83 (6.9%)                      |       |
| North America      | 146 (12.3%)         | 158 (13.0%)                    |       |
| Western Europe     | 327 (27.6%)         | 317 (26.2%)                    |       |
| Comorbidities, n (%) |                    |                                |       |
| Prior MI           | 306 (25.8%)         | 333 (27.5%)                    | 0.36  |
| Ischemic etiology  | 476 (40.2%)         | 507 (41.9%)                    | 0.40  |
| Atrial fibrillation| 369 (31.4%)         | 401 (33.1%)                    | 0.36  |
| Prior HF Hospitalization | 631 (53.3%) | 622 (51.4%)                    | 0.34  |
| Hypertension       | 1145 (96.7%)        | 1170 (96.6%)                   | 0.90  |
| Stroke             | 120 (10.2%)         | 152 (12.6%)                    | 0.06  |
| Obesity (BMI ≥ 30 kg/m²) | 686 (57.9%) | 679 (56.1%)                    | 0.36  |
| CKD (eGFR < 60 ml/min/1.73 m²) | 614 (51.9%) | 593 (49.0%)                    | 0.16  |
| NYHA functional class, n (%) |          |                                | 0.51  |
| 1                  | 42 (3.5%)           | 37 (3.1%)                      |       |
| 2                  | 890 (75.2%)         | 910 (75.2%)                    |       |
| 3                  | 245 (20.7%)         | 260 (21.5%)                    |       |
| 4                  | 7 (0.6%)            | 3 (0.2%)                       |       |
| LVEF (percent)     | 57.2 ± 8.0          | 57.2 ± 7.8                     | 0.98  |
| SBP, mmHg          | 131 ± 15            | 132 ± 16                       | 0.45  |
| DBP, mmHg          | 74 ± 10             | 74 ± 11                        | 0.79  |
| Heart rate, bpm    | 71 ± 12             | 72 ± 12                        | 0.07  |
| BMI, kg/m²         | 31.2 ± 4.9          | 30.9 ± 4.9                     | 0.16  |
| eGFR, ml/min/1.73 m² | 62 ± 20         | 63 ± 19                        | 0.29  |
| HbA1c, percent     | 73.2 ± 1.43         | 73.7 ± 1.48                    | 0.44  |
| NT-proBNP, pg/ml   | 578 [281–1125]      | 564 [282–1142]                 | 0.66  |
| Medications, n (%) |                      |                                |       |
| Beta blockers      | 969 (81.8%)         | 998 (82.4%)                    | 0.72  |
| Diuretics          | 1138 (96.1%)        | 1159 (95.7%)                   | 0.61  |
| MRA                | 316 (26.7%)         | 308 (25.4%)                    | 0.48  |
| Insulin            | 319 (26.9%)         | 338 (27.9%)                    | 0.60  |
| GLP-1 receptor agonists | 10 (0.8%)  | 10 (0.8%)                      | 0.96  |
| Oral glucose lowering |                   |                                |       |
| Metformin          | 563 (47.6%)         | 572 (47.2%)                    | 0.88  |
| Sulfonylurea       | 250 (21.1%)         | 230 (19.0%)                    | 0.19  |
| SGLT-2 inhibitors  | 14 (1.2%)           | 14 (1.2%)                      | 0.95  |
| DPP-4 inhibitors   | 150 (12.7%)         | 148 (12.2%)                    | 0.74  |
Table 1 (continued)

| Data are presented as mean ± SD, median [Q1–Q3] or n (%) |
|----------------------------------------------------------|
| **BMI** body mass index, **CCB** calcium channel blocker, **CKD** chronic kidney disease, **DBP** diastolic blood pressure, **DPP-4** dipeptidyl peptidase-4, **eGFR** estimated glomerular filtration rate, **GLP-1** glucagon-like peptide-1, **HF** heart failure, **LVEF** left ventricular ejection fraction, **MRA** mineralocorticoid receptor antagonists, **NT-proBNP** N-terminal prohormone B-type natriuretic peptide, **SBP** systolic blood pressure, **SGLT-2** sodium glucose cotransporter-2 |

### Table 2

| Mean HbA1c values at randomization and at follow-up, in PARAGON-HF participants with diabetes, by treatment groups |
|----------------------------------------------------------|
| Valsartan, n = 1184 | Sacubitril/valsartan, n = 1211 | Adjusted difference in change from randomization (95% CI) | P value |
|---------------------|-------------------------------|------------------------------------------------------------|----------|
| **HbA1c (percent)** |                               |                                                            |          |
| Randomization       | 7.32 ± 1.43                   | 7.37 ± 1.48                                                 | –        |
| Week 48             | 7.30 ± 1.57                   | 7.10 ± 1.37                                                 | −0.24 (− 0.33 to − 0.16) | < 0.001  |
| Week 96             | 7.17 ± 1.55                   | 7.11 ± 1.46                                                 | −0.12 (− 0.22 to − 0.01) | 0.027    |
| Week 144            | 7.13 ± 1.46                   | 7.08 ± 1.52                                                 | −0.13 (− 0.26 to − 0.003) | 0.044    |

Between-group differences in changes from randomization were adjusted for randomization HbA1c values. Number of patients with HbA1c measurements at randomization: n = 2394 (val: n = 1183, sac/val: n = 1211), at week 48: n = 2143 (val: n = 1056, sac/val: n = 1087), at week 96: n = 1947 (val: n = 958, sac/val: n = 989), at week 144: n = 1378 (val: n = 693, sac/val: n = 685)

**New use of antihyperglycemic medications**

At randomization, there were 1738 patients with diabetes who did not use insulin. The proportion of patients with diabetes who initiated insulin treatment during follow-up was lower in the sacubitril/valsartan group than in the valsartan group, but the difference did not reach statistical significance (12.8% vs. 16.1%; HR: 0.80, 95% CI 0.62–1.02, P = 0.07). Among the 634 patients with diabetes who did not use any antihyperglycemic drugs at randomization, the proportions of patients who initiated treatment with non-insulin antihyperglycemic medications were similar between treatment groups (13.7% vs. 15.7%; HR: 0.88, 95% CI 0.58–1.32, P = 0.53). The proportions of patients who initiated treatment with metformin did also not differ significantly between groups (9.3% vs. 13.5%, HR 0.69, 95% CI 0.43–1.09, P = 0.11).

The proportion of women was similar in patients who initiated or not initiated insulin treatment (46.6% vs. 50.4%, P = 0.27) and in patients who initiated or not initiated non-insulin antihyperglycemic medications (47.3% vs. 54.3%, P = 0.21), respectively. The cumulative incidences of new use of insulin and of non-insulin antihyperglycemic medications, respectively, are shown by treatment groups in Fig. 2.

**Hypoglycemia**

Overall, 82 patients with diabetes had at least one investigator-reported hypoglycemic adverse event. Sixty-seven
of these events (81.7%) occurred in patients who used either insulin or sulfonylurea (or both) at baseline. The distribution of first hypoglycemic adverse events is shown in Additional file 1: Table S2. Patients with diabetes who experienced at least one hypoglycemic adverse event were of similar age as patients with diabetes who did not experience any hypoglycemic adverse event (72.3 ± 7.9 years vs. 72.0 ± 8.3 years, P = 0.78), and there was no significant difference in the proportion of women (50.0% vs. 49.3%, P = 0.90). Patients with diabetes who experienced at least one hypoglycemic adverse event had significantly higher baseline HbA1c (7.67 ± 1.50% vs. 7.33 ± 1.46%, P = 0.042), were more likely to use insulin (62.2% vs. 26.2%, P = 0.001) or sulfonylureas (28.0% vs. 19.8%, P = 0.07) but the latter finding did not meet statistical significance. The incidence of first hypoglycemic adverse events was significantly higher in patients with diabetes in the sacubitril/valsartan group than in patients with diabetes in the valsartan group (4.2% vs. 2.6%; HR 1.64, 95% CI 1.05–2.56, P = 0.030). In the 1064 patients with diabetes who used either insulin or sulfonylurea or both at baseline, the same conclusion was drawn but the incidence of first hypoglycemic adverse events was higher (7.8% vs. 4.8%; HR 1.66, 95% CI 1.02–2.71, P = 0.043), whereas in patients with diabetes who used neither insulin nor sulfonylurea at baseline (n = 1331), no significantly increased risk was observed in the sacubitril/valsartan group (1.5% vs. 0.8%; HR 1.92, 95% CI 0.65–5.61, P = 0.24).

In patients with diabetes who used metformin but who did not use neither insulin nor sulfonylurea at baseline (n = 593), there were only nine first hypoglycemic adverse events and there was not a significantly higher risk for hypoglycemic adverse events in the sacubitril/valsartan group (2.0% vs. 1.0%; HR 1.92, 95% CI 0.48–7.69, P = 0.36). In an analysis of all patients (with or without diabetes) who did not use glucose-lowering medications at baseline (n = 3035), there were 7 first hypoglycemic adverse events and no significantly increased risk was observed in the sacubitril/valsartan group (0.3% vs. 0.2%; HR 1.31, 95% CI 0.29–5.86, P = 0.72). The cumulative incidence of first hypoglycemic adverse events in patients with diabetes is shown by randomization groups in Fig. 2.

### Body weight, triglycerides, and new diabetes

Mean values of body weight and of triglyceride levels at randomization and at weeks 48, 96 and 144 are shown in Additional file 1: Fig. S2, Table S3. In patients with diabetes, body weight increased more in patients randomized to sacubitril/valsartan than to valsartan (average yearly treatment effect of sacubitril/valsartan: 0.27 kg (95% CI 0.06 to 0.49 kg, P = 0.012) and triglycerides increased more in patients randomized to valsartan (average yearly treatment effect of sacubitril/valsartan: −0.05 mmol/l (95% CI −0.08 to −0.02 mmol/l, P = 0.003). Among the 2401 patients who did not have diabetes at randomization, the incidence of adjudicated new-onset diabetes was 9/1196 in the sacubitril/valsartan group and 12/1205 in the valsartan group (HR 0.74, 95% CI 0.31–1.76, P = 0.50).

### Pooled analyses of PARAGON-HF and PARADIGM-HF

To assess the effects on glycemia of sacubitril/valsartan across the spectrum of LVEF in patients with heart failure, we explored interactions between LVEF and treatment effects in a pooled patient-level analysis of patients with diabetes from the PARAGON-HF and PARADIGM-HF trials. Pooled analyses of the primary outcomes of these two heart failure trials were pre-specified, and have been published previously [20]. Left ventricular ejection fraction did not significantly modify the treatment effect
of sacubitril/valsartan compared with control treatment on HbA1c ($P_{\text{interaction}} = 0.56$, Fig. 3), and neither did baseline BMI ($P_{\text{interaction}} = 0.06$). There was no significant association between change in HbA1c and change in eGFR ($P = 0.08$).

At 48 weeks, the reduction in mean HbA1c was larger in the sacubitril/valsartan group than in the control group, with a baseline-adjusted between-group difference in change in mean HbA1c of $-0.19\%$ (95% CI $-0.25$ to $-0.13\%$, $P < 0.001$). In patients who also had available data for NT-proBNP at randomization and at week 48 (PARAGON-HF, $n = 1489$) or week 32 (PARADIGM-HF, $n = 757$), this difference remained significant after additional adjustment for change in NT-proBNP ($-0.17$, 95% CI $-0.25$ to $-0.09$, $P < 0.001$). The proportions of patients with diabetes who initiated insulin treatment during follow-up was significantly lower in the sacubitril/valsartan group than in the control group (9.3% vs. 12.4%; HR 0.75, 95% CI 0.63–0.89, $P = 0.001$), and this was not significantly modified by LVEF ($P_{\text{interaction}} = 0.93$; Fig. 3). Among the patients with diabetes who did not use any antihyperglycemic medications at randomization, the proportion who initiated treatment with non-insulin antihyperglycemic medications was numerically lower in the sacubitril/valsartan group than in the control group (11.5% vs. 14.3%; HR 0.80, 95% CI 0.64–1.01, $P = 0.06$) and this was not significantly modified by LVEF ($P_{\text{interaction}} = 0.93$; Fig. 3). New use of metformin also occurred less often in the sacubitril/valsartan group than in the control group (6.8% vs. 9.2%, HR 0.73, 95% CI 0.54–0.98, $P = 0.035$).

Overall, there were 179 patients with diabetes who had at least one investigator-reported hypoglycemic adverse event. One hundred and forty-nine of these events (83.2%) occurred in patients who used either insulin or sulfonylurea (or both) at baseline. The distribution of first hypoglycemic adverse events is shown in Additional file 1: Table S2. The incidence of first hypoglycemic adverse events was significantly higher in patients with diabetes randomized to sacubitril/valsartan than in patients with diabetes randomized to the control group (3.3% vs. 2.5%; HR: 1.37, 95% CI 1.02–1.84, $P = 0.038$) and without a significant interaction between LVEF and treatment effect ($P_{\text{interaction}} = 0.81$, Fig. 3). In the subgroup of patients with diabetes who used either insulin or sulfonylurea or both at baseline ($n = 2493$) the risk was higher with sacubitril/valsartan (7.0% vs. 5.0%; HR 1.42 (95% CI 1.03–1.97, $P = 0.034$), whereas in patients
with diabetes who used neither insulin nor sulfonylurea at baseline (n = 3680) did not significantly increased risk was observed in the sacubitril/valsartan group (1.0% vs. 0.7%; HR 1.43, 95% CI 0.69–2.97, P = 0.34). In patients with diabetes who used metformin but who did not use neither insulin nor sulfonylurea at baseline (n = 1035) there were 16 first hypoglycemic adverse events and there was not a significantly higher risk for hypoglycemic adverse events in the sacubitril/valsartan group (1.9% vs. 1.2%; HR 1.57, 95% CI 0.57–4.31, P = 0.39). In an analysis of all patients (with or without diabetes) who did not use glucose-lowering medications at baseline (n = 9261), there were 17 first hypoglycemic adverse events and no significantly increased risk was observed in the sacubitril/valsartan group (0.2% vs. 0.1%; HR 1.81, 95% CI 0.67–4.90, P = 0.24). The cumulative incidences of new use of insulin, of new use of non-insulin antihyperglycemic medications, and of first hypoglycemic adverse events in the pooled cohort are shown by randomization groups in Additional file 1: Fig. S3.

**Discussion**

We found that in patients with HFpEF and diabetes, sacubitril/valsartan significantly reduced HbA1c compared with valsartan, and that new use of insulin was numerically lower in patients randomized to sacubitril/valsartan than in patients randomized to valsartan. In a pooled analysis of patient-level data from patients in the PARADIGM-HF and PARAGON-HF trials, the effects of treatment with sacubitril/valsartan on HbA1c reduction and on new use of insulin were similar across the spectrum of LVEF. While these results suggest potentially beneficial effects, we also found a slightly increased risk for hypoglycemic adverse events with sacubitril/valsartan. These findings have implications for the treatment of patients with heart failure and diabetes.

Our finding that sacubitril/valsartan reduced HbA1c in patients with HFpEF and diabetes is consistent with what was observed in patients with HREF and diabetes in the PARADIGM-HF trial [12], in which sacubitril/valsartan reduced HbA1c compared with enalapril. The incremental reductions in HbA1c observed with sacubitril/valsartan compared with valsartan in PARAGON-HF or with enalapril in PARADIGM-HF are small, but appear to be consistent across the spectrum of LVEF and to be sufficient to decrease the requirement for insulin. Expectedly, the reduction of HbA1c that was observed with sacubitril/valsartan in patients without diabetes at baseline was considerably smaller in magnitude, which may be an explanation to why we did not observe a reduced incidence of new diabetes. We did not observe any significant associations between changes in HbA1c and changes in renal function, which may be due to the small magnitude of the HbA1c reduction and the relatively short follow-up time.

The mechanisms by which sacubitril/valsartan might lower HbA1c remain unclear. Sacubitril inhibits the endopeptidase neprilysin which promotes the proteolytic cleavage and inactivation of natriuretic peptides and other vasoactive peptides [21]. In observational cohort studies, higher levels of natriuretic peptides have been associated with lower measures of insulin resistance in obese as well as non-obese individuals [22], and with decreased risk for new-onset diabetes [23, 24]. Mendelian randomization studies of a common variant of the B-type natriuretic peptide (BNP) gene locus have suggested that these inverse relationships between natriuretic peptide levels and the risk for new onset diabetes may be causal [25]. The mechanisms by which natriuretic peptides may affect glucose metabolism and insulin resistance remain to be determined, but may involve increased secretion of the insulin-sensitizing hormone adiponectin, decreased secretion of pro-inflammatory cytokines from the adipose tissue, and increased insulin secretion [26]. An alternative explanation for the beneficial glycemic effects observed with sacubitril/valsartan may be decreased degradation of the antihyperglycemic incretin hormone glucagon-like peptide-1 (GLP-1) [27]. Glucagon-like peptide-1 is a known substrate for neprilysin in vitro [28], and animal studies have suggested that up to 50% of exogenously infused GLP-1 may be degraded by neprilysin [29]. In patients with heart failure who were switched from angiotensin converting enzyme inhibitors or angiotensin receptor blockers to sacubitril/valsartan, a dose-dependent increase of circulating GLP-1 levels has been described, which correlated with a decrease in levels of the protein glycation biomarker fructosamine [30]. Finally, it is known that insulin resistance increases with increasing heart failure severity [31], and although the treatment effect on HbA1c remained statistically significant after adjustment for changes in levels of NT-proBNP, it remains plausible that sacubitril/valsartan improved measures of glycemia by reducing worsening of heart failure progression over time.

Observational data have shown that use of insulin is associated with an adverse prognosis in people with heart failure and diabetes [5, 8, 9], and that higher HbA1c is a risk factor for developing heart failure in people with diabetes [6, 7]. Therefore, although the treatment effects were numerically small, the improvement in HbA1c and the reduced need to initiate insulin treatment that was observed with sacubitril/valsartan in this secondary analysis may benefit people with heart failure and diabetes. The slightly increased risk for hypoglycemia that was observed should not discourage use of sacubitril/valsartan, given its beneficial effects on morbidity and
mortality [10, 11]. It should also be noted that in stratified analyses, sacubitril/valsartan was associated with significantly higher risk for hypoglycemic adverse events only in patients with diabetes who used either insulin or sulfonylurea at baseline. In people with heart failure and diabetes who experience hypoglycemia, conventional strategies should be recommended (such as patient education, increased frequency of self-measurement of blood glucose, and possibly dose adjustments of insulin or sulfonylurea) regardless of whether the patient is treated with sacubitril/valsartan.

**Study limitations and strengths**

Some limitations of this analysis should be noted. The PARAGON-HF trial was not primarily designed to detect changes in HbA1c, changes in antihyperglycemic medications, or hypoglycemia. Changes in HbA1c were observed against the background of therapeutic treatment decisions that took place outside of the study protocol. Hypoglycemia was assessed as investigator-reported adverse events without a requirement for biochemical confirmation. While new onset diabetes was a pre-specified exploratory outcome in PARAGON-HF, there were a very small number of adjudicated cases of new diabetes, and although the adjudication criteria required hyperglycemia to be present on at least two occasions, the adjudication criteria did not specifically mandate confirmation of hyperglycemia with two different test methods. The statistical power for this outcome was low. We did not have data that allowed us to differentiate between type 1 and type 2 diabetes. Finally, we did not analyze dose adjustments or changes between different drug classes of antihyperglycemic medications. Strengths of this study include the randomized controlled design and the careful characterization of all patients at baseline and during follow-up. The pooled analyses of patients from the PARAGON-HF and PARADIGM-HF trials made exploratory analyses across the spectrum of LVEF possible, including patients who fulfilled the recently proposed criteria [32] for either HFrEF, heart failure with mildly reduced ejection fraction (HFmrEF) or HFpEF.

**Conclusions**

In summary, these data indicate that the glucose-lowering effect of sacubitril/valsartan, as evidenced by a small but significant reduction in HbA1c and new use of insulin, was similar in heart failure patients with diabetes across the spectrum of LVEF. While the overall magnitude of the HbA1c lowering effect of sacubitril/valsartan was modest and the overall occurrence of hypoglycemic adverse events was low, clinicians should be aware of the possibility of improved glycemic control and reduced need for insulin, when initiating therapy with sacubitril/valsartan in patients with diabetes.

**Abbreviations**

BNP: B-type natriuretic peptide; FDA: Food and Drug Administration; GLP-1: Glucagon-like peptide-1; HFmrEF: Heart failure with mildly reduced ejection fraction; HFpEF: Heart failure with preserved ejection fraction; HFrEF: Heart failure with reduced ejection fraction; LVEF: Left ventricular ejection fraction; MRA: Mineralocorticoid receptor antagonist; PARAGON-HF: Prospective comparison of angiotensin receptor-neprilysin inhibitor with angiotensin-converting enzyme inhibitor to determine impact on global mortality and morbidity in heart failure; PARAGON-HF: The prospective comparison of angiotensin receptor–neprilysin inhibitor with angiotensin-converting-enzyme inhibitor to improve outcomes in heart failure with preserved ejection fraction; SGLT-2: Sodium–glucose cotransporter-2.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12933-022-01545-1.

**Additional file 1:** Figure S1. Numbers of PARAGON-HF participants fulfilling the three criteria used to define diabetes at baseline. Table S1. Baseline characteristics of PARAGON-HF participants by diabetes status. Table S2. Distribution of first investigator-reported hypoglycemic adverse events (AE) in PARAGON-HF and PARADIGM-HF participants with diabetes. Table S3. Average body weight and triglyceride levels at randomization and at follow-up in PARAGON-HF participants with diabetes, by treatment groups. Figure S2. Average body weight and triglyceride levels at randomization and at follow-up, in PARAGON-HF participants with diabetes, by treatment groups. Figure S3. Cumulative incidence of different outcomes in PARAGON-HF and PARADIGM-HF participants with diabetes.

**Acknowledgements**

Not applicable.

**Author contributions**

MOW, BC and SDS designed the present secondary analysis, analyzed data and prepared the manuscript draft. All authors contributed to meaningful interpretation of the data, reviewed and edited the manuscript. All authors read and approved the final manuscript.

**Funding**

The PARAGON-HF and PARADIGM-HF studies were funded by Novartis. MOW is supported by grants from The Swedish Heart Association, The Swedish Society of Medicine and Region Östergötland, Sweden. JWJ has received a National, Heart, Lung, and Blood Institute postdoctoral training grant (T32HL094301). SJS is supported by grants from the National Institutes of Health (R01 HL107577, R01 HL127028, R01 HL140731, and R01 HL149423). JJVM is supported by a British Heart Foundation Centre of Research Excellence Grant (RE/18/6/34217).

**Availability of data and materials**

The trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

**Declarations**

**Ethics approval and consent to participate**

The study was approved by the appropriate national and institutional regulatory and ethics boards and all patients provided written informed consent.

**Consent for publication**

Not applicable.
Competing interests
MOW has served on advisory boards or lectured for MSD, Lilly, Novo Nordisk and Sanofi, and has organized a professional regional meeting sponsored by Lilly, Robin Medical, Sanofi, Novartis and Novo Nordisk. BC reports consulting for Amgen, Boehringer Ingelheim, Corvia, MyoKardia, Novartis. MV has received research grant support or served on advisory boards for American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Cytokinetics, Lexicon Pharmaceuticals, Relypsa, and Roche Diagnostics, speaker engagements with Novartis and Roche Diagnostics, and participates on clinical endpoint committees for studies sponsored by Galmed and Novartis. MR reports the following disclosures: Abbvie, Actavis, Amgen, Aminar, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Casana, CSL Behring, Cytokinetics, Johnson & Johnson, Lilly, Moderna, Novartis, ParatusRx, Pfizer, Relypsa, Salamandra, Synthetic Biologics, Thervix: MAV reports consulting for Novartis, and is a member of the steering committees for both PARADIGM-HF and PARAGON-HF. JR reports the following disclosures: Consultant Novartis, Aventis, AstraZeneca, Bayer, Myokardia/BMS. KS reports honoraria from AstraZeneca, Bayer-Mannheim, Novartis. ML is a full-time employee of Novartis Pharmaceuticals. SJS has received research grants from Actelion, AstraZeneca, Corvia, Novartis, and Pfizer, and has served consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Axon Therapeutics, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Cardior, CVRx, Cytokinetics, Edwards, Eisai, Ionis, Ironwood, Merck, MyoKardia, Novartis, Prothena, Pfizer, Regeneron, Sanofi, Shire, Tenax, and United Therapeutics. MAP reports research grant support to institution from Novartis, serves on PARAGON-HF Steering Committee and Study Chair of PARADISE-MI reports consulting for AstraZeneca, Boehringer Ingelheim and Eli Lily Alliance, Covvidia, DaiCor, Gla- oSmithKline, NHLBI CONNECTs (Master Protocol Committee), Novartis, Novo Nordisk, Peerbridge and Sanofi; and has equity in DaiCor and Peerbridge. JVIM reports payments to his employer, Glasgow University, for his work on clinical trials, consulting and other activities: Alynym, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardurion, Cytokinetics, Dai- Cor-GSK, Ionis, KBI Biosciences, Novartis, Pfizer, Theracos, and personal payments: Abbott, Alkem Metabolics, Eris Lifesciences, Hikma, Ionis, Lupin, ProAdWise Communications, Sun Pharmaceuticals, Servier. SDS has received research grants from Actelion, Alynym, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lilly, Merck, MyoKardia, NIH/NHLBI, Neurotonik, Novartis, NovoNordisk, Respcardia, Sanofi Pasteur, Theracos, and has consulted for Abbott, Action, Akros, Alynym, Arena, AstraZeneca, Bayer, Boehringer-Ingelheim, BMS, Cardio, Cardurion, Corvia, Cytokinetics, Dai- ichi-Sankyo, GSK, Lilly, Merck, MyoKardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sceptra, JCV, RR and AJ report no disclosures.

Author details
1 Cardiovascular Division, Brigham & Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. 2Department of Internal Medicine, Department of Health, Medicine and Caring Sciences, Linköping University, Norrköping, Sweden. 3 Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark. 4 British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK. 5Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX, USA. 6 Imperial College, London, UK. 7 Medical University of South Carolina and Ralph H. Johnson Veterans Affairs Medical Center, Charleston, SC, USA. 8 Montreal Heart Institute, University of Montreal, Montreal, Canada. 9 Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg, Sweden. 10 Novartis, East Hanover, NJ, USA. 11 Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Received: 11 April 2022 Accepted: 5 June 2022
Published online: 18 June 2022

References
1. MacDonald MR, Petrie MC, Varnani F, Ostergren J, Michelson EL, Young JB, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the candesartan in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2008;29(11):1377–85.
2. Aguilar D, Deswal A, Ramasubbu K, Mann DL, Bozkurt B. Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol. 2010;105(3):373–7.
3. Kristensen SL, Mogensen UM, Jønud PS, Petrie MC, Preiss D, Win S, et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the l-pressurE trial (IsarbetaN in heart failure with preserved ejection fraction). Circulation. 2017;135(8):724–35.
4. Tribouilloy C, Rusinuau D, Mahjoub H, Tarteire JM, Kesri-Tarteire L, Godard S, et al. Prognostic impact of diabetes mellitus in patients with heart failure and preserved ejection fraction: a prospective five-year study. Heart. 2008;94(11):1450–5.
5. Jackson AM, North R, Liu J, Kristensen SL, Anand IS, Claggett BL, et al. Diabetes and pre-diabetes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2022;24(5):497–509.
6. Lind M, Bounias I, Olsson M, Godbjurmdottir S, Svensson AM, Rosen- gren A. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet. 2011;378(9786):140–6.
7. Lind M, Olsson M, Rosengren A, Svensson AM, Bounias I, Godbjurmdottir S. The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia. 2012;55(11):2496–503.
8. Huyhn T, Harty BJ, Craggett B, Fleg JL, McKinlay SM, Anand IS, et al. Comparison of outcomes in patients with diabetes mellitus treated with versus without insulin + heart failure with preserved left ventricular ejection fraction (from the TOPCAT study). Am J Cardiol. 2019;123(4):611–7.
9. Vaduganathan M, Claggett BL, Chatterjee NA, Anand IS, Sweitzer NK, Fang JC, et al. Sudden death in heart failure with preserved ejection fraction: a competing risks analysis from the TOPCAT trial. JACC Heart Fail. 2019;6(8):653–61.
10. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizzkwa AR, et al. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.
11. Solomon SD, McMurray J, Anand IS, Ge J, Lam CSP, Maggioni AP, et al. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019;381(17):1609–20.
12. Seferovic JP, Craggett B, Seidellmann SB, Seely EW, Packer M, Zile MR, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017;5(5):333–40.
13. Jordan J, Stinkens R, Jax T, Engeli S, Blak EE, May M, et al. Improved insu- lin sensitivity with angiotensin receptor neprilysin inhibition in individuals with obesity and hypertension. Clin Pharmacol Ther. 2017;101(2):254–63.
14. Solomon SD, Rizkwa AR, Gong J, Wang W, Anand IS, Ge J, et al. Angiotensin- neprilysin receptor inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail. 2017;5(7):471–82.
15. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizzkwa AR, et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic sys- tolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15(9):1062–73.
16. Mayer TK, Freedman ZR. Protein glycosylation in diabetes mellitus: a review of laboratory measurements and of their clinical utility. Clin Chim Acta. 1983;127(2):147–84.
17. Vaduganathan M, Craggett B, Packer M, McMurray J, Rouleau JL, Zile MR, et al. Natriuretic peptides as biomarkers of treatment response in clinical trials of heart failure. JACC Heart Fail. 2018;6(7):564–9.
18. Cunningham JW, Vaduganathan M, Craggett BL, Zile MR, Anand IS, Packer M, et al. Effects of sacubitril/valsartan on N-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction. JACC Heart Fail. 2020;8(5):372–81.
19. Zile MR, Craggett BL, Prescott MF, McMurray JJ, Packer M, Rouleau JL, et al. Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure. J Am Coll Cardiol. 2011;68(2):2425–36.
20. Solomon SD, Vaduganathan M, Claggett BL, Packer M, Zile M, Swedberg K, et al. Sacubitril/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020;141(5):352–61.

21. Hund P, McMurray JJ. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan. Heart. 2016;102(17):1342–7.

22. Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, McCabe EL, et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab. 2011;96(10):3242–9.

23. Magnusson M, Juicic A, Hedblad B, Engstrom G, Persson M, Struck J, et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo diet and cancer study. J Clin Endocrinol Metab. 2012;97(2):638–45.

24. Lazo M, Young JH, Brancati FL, Coresh J, Whelton S, Ndumele CE, et al. N-terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes. 2013;62(9):3189–93.

25. Pfister R, Sharp S, Luben R, Welsh P, Barroso I, Salomaa V, et al. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med. 2011;8(10):e1001112.

26. Verbien K, Hansen D, Jocken JWE, Bliak EE. Natriuretic peptides in the control of lipid metabolism and insulin sensitivity. Obes Rev. 2017;18(11):1243–59.

27. Giamouzis G, Butler J. Glycaemic control in heart failure: a PARADIGM shift for patients with concomitant diabetes? Lancet Diabetes Endocrinol. 2017;5(5):314–5.

28. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Goke R, Goke B, Thole H, et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36)amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept. 1995;58(3):149–56.

29. Plamboeck A, Holst JJ, Carr RD, Deacon CF. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig. Diabetologia. 2005;48(9):1882–90.

30. Nougue H, Pezel T, Picard F, Sadoune M, Arrigo M, Beauvais F, et al. Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study. Eur J Heart Fail. 2019;21(5):598–605.

31. Swan JW, Anker SD, Walton C, Godsland IF, Clark AL, Leyva F, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol. 1997;30(2):527–32.

32. Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report from the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure. Eur J Heart Fail. 2021;23(3):352–80.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.